Bayer-backed Pyxis debuts with $22M to pursue new immuno-oncology targets

Pyxis’ tumor microenvironment-based technology to identify immuno-oncology targets developed by cancer researcher Thomas Gajewski prompted Leap by Bayer to lead the start-up’s $22 million series A round.

Agent Capital, Ipsen Group (Euronext:IPN; Pink:IPSEY), Longwood and angel investors, including the University of Chicago Startup Investment Program, also participated in the round for Pyxis Oncology Inc. (Boston, Mass.), which in addition to Gajewski counts Longwood and life sciences executive and investor John Flavin as co-founders...